Press release
February 23, 2026
Braveheart Bio to Participate in TD Cowen 46th Annual Health Care Conference
Braveheart Bio, Inc. (BRVE)
SAN FRANCISCO, February 23, 2026: Braveheart Bio, a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that it will participate in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026, in